- Conditions
- Heart Failure, Reduced Ejection Fraction
- Interventions
- sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 47
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension,Essential
- Interventions
- Captopril Pill, Enalapril Pill, Hydrochlorothiazide
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertension
- Interventions
- Aliskiren, Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
- Conditions
- Hypertension
- Interventions
- Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Endocrine System Diseases
- Interventions
- Metformin, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil and enalapril, avanafil and amlodipine
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 40 Years to 65 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Breast Cancer
- Interventions
- doxorubicin hydrochloride, enalapril maleate
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Edina, Minnesota • Minneapolis, Minnesota
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Equivalent dose enalapril, Equivalent dose lisinopril
- Drug
- Lead sponsor
- Memorial Health University Medical Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Savannah, Georgia
- Conditions
- Hypertension, Left Ventricular Hypertrophy
- Interventions
- Eplerenone, Chlorthalidone, Potassium
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
- Interventions
- Losartan
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure and Reduced Ejection Fraction
- Interventions
- LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
- Conditions
- Pediatric Heart Failure
- Interventions
- LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Interventions
- Blood pressure management policies
- Other
- Lead sponsor
- The George Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure, Congestive
- Interventions
- Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
- Drug
- Lead sponsor
- Heart Center Research, LLC
- Network
- Eligibility
- 19 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Stage D Heart Failure
- Interventions
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Chronic Heart Failure
- Interventions
- Enalapril, Aliskiren
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 58
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
- Conditions
- Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- enalapril maleate, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 8 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 43 more
- Conditions
- Hypertension in Pregnancy
- Interventions
- Enalapril 10mg QD, Nifedipine 30mg XL BID
- Drug
- Lead sponsor
- Nebraska Methodist Health System
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive
- Interventions
- Enalapril, Placebo
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina + 3 more
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Interventions
- Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee